Emergent BioSolutions is facing a fresh set of manufacturing troubles as the FDA issued a warning to the company regarding its Baltimore site.
Emergent revealed in an SEC filing on Friday that the US regulator issued a warning letter on Aug. 10, flagging two areas of concern at the company’s Camden manufacturing facility in Baltimore.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,